<DOC>
	<DOCNO>NCT02313272</DOCNO>
	<brief_summary>The purpose study see addition investigation drug call pembrolizumab ( Keytruda® ) radiation therapy bevacizumab ( Avastin® ) safe help control growth tumor , participant recurrent high grade glioma .</brief_summary>
	<brief_title>Hypofractionated Stereotactic Irradiation ( HFSRT ) With Pembrolizumab Bevacizumab Recurrent High Grade Gliomas</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Histologically confirm diagnosis World Health Organization ( WHO ) Grade III ( except anaplastic oligodendroglioma ) IV malignant glioma . Documented recurrence diagnostic biopsy contrast enhance magnetic resonance imaging ( MRI ) perform within 28 day entry trial per Response Assessment Criteria HighGrade Gliomas ( RANO ) Criteria . Patients recurrent WHO Grade III gliomas receive one prior treatment recurrent high grade disease . Maximum diameter enhance tumor ( target lesion ) ≤ 3.5 cm . Interval ≥ 6 month end prior radiation therapy require unless new recurrence outside previous radiotherapy treatment field . Previous first line treatment least standard dose radiotherapy ( total dose ≥ 54 Gy ) temozolomide . Interval ≥ 4 week since surgical resection prior entry trial . Interval ≥ 4 week last administration investigational agent prior cytotoxic therapy ( except bevacizumab ) . There 14 day interval last dose bevacizumab first day treatment study . Age 18 year old day signing inform consent . Karnofsky performance status ≥ 70 . Demonstrate adequate organ function . Resting baseline O2 saturation pulse oximetry ≥ 92 % rest . Must recover toxic effect prior therapy . Willing able provide write informed consent/assent trial . Life expectancy ≥ 12 week . Female participant childbearing potential negative urine serum pregnancy within 72 hour prior receive first dose study medication . Must willing use 2 method birth control surgically sterile , abstain heterosexual activity course study 120 day last dose study medication . Male participant agree use adequate method contraception start first dose study therapy 120 day last dose study therapy . More 3 recurrence high grade glioma . Has anaplastic oligodendroglioma . Has receive reradiation recurrent disease ( standard frontline adjuvant radiation therapy ) . Recurrent tumor near brainstem optic chiasm must receive prior radiation therapy . Infratentorial , leptomeningeal evidence recurrent disease . Recurrent persistent tumor ( enhance area ) great 3.5 cm maximum diameter . Prior treatment Gliadel unless administer first line treatment ≥ 3 month prior study treatment . Unable ( due existent medical condition ) unwilling contrast enhance MRI brain . Currently participate participate study investigational agent use investigational device within 4 week first dose treatment . Diagnosis immunodeficiency receive systemic immunosuppressive therapy within 7 day prior first dose trial treatment . Physiologic dose steroid therapy ( ≤ 10 mg/day prednisone equivalent ) allow . Prior chemotherapy , target small molecule therapy , monoclonal antibody ( except bevacizumab ) within 4 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due agent administer 4 week earlier . Wash period bevacizumab 14 day . Known additional malignancy progress require active treatment . Exceptions include basal cell carcinoma skin , squamous cell carcinoma skin , situ cervical cancer undergone potentially curative therapy . Active autoimmune disease require systemic treatment within past 3 month document history clinically severe autoimmune disease , syndrome require systemic steroid immunosuppressive agent . Evidence interstitial lung disease active , noninfectious pneumonitis . Active infection require systemic therapy . Prior allergic reaction Bevacizumab . History uncontrolled hypertension , hypertensive crisis hypertensive encephalopathy . History nonhealing wound , ulcer , bone fracture within 90 day ( 3 month ) prior entry trial . History gastrointestinal bleeding hemorrhage/bleeding event ≥ grade 3 ( CTCAE , v. 4 ) within 30 day prior entry trial . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior day 1 treatment study . Requires escalate chronic supraphysiologic dos corticosteroid ( &gt; 10 mg/day prednisone equivalent ) . History current evidence condition , therapy , laboratory abnormality might confound result trial , interfere subject 's participation full duration trial , best interest subject participate , opinion treat investigator . Known psychiatric substance abuse disorder would interfere cooperation requirement trial . Pregnant breastfeeding , expect conceive father child within project duration trial , start prescreening screen visit 120 day last dose trial treatment . Prior therapy antiProgrammed Death 1 ( PD1 ) , antiProgrammed Death1 Ligand 1 ( PDL1 ) , antiPDL2 , antiCD137 , antiCytotoxic Tlymphocyteassociated antigen4 ( CTLA4 ) antibody ( include ipilimumab antibody drug specifically target Tcell costimulation checkpoint pathway ) . Known history Human Immunodeficiency Virus ( HIV ) ( HIV 1/2 antibody ) . Known active Hepatitis B . Has receive live vaccine within 30 day prior first dose trial treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>neoplasm</keyword>
	<keyword>high-grade glioma</keyword>
	<keyword>recurrent glioma</keyword>
	<keyword>glioma</keyword>
	<keyword>Hypofractionated Stereotactic Irradiation ( HFSRT )</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Pembrolizumab</keyword>
	<keyword>recurrent high-grade glioma</keyword>
	<keyword>Grade III malignant glioma</keyword>
	<keyword>Grade IV malignant glioma</keyword>
	<keyword>brain nervous system</keyword>
</DOC>